Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease
Journal of Huntington's Disease · 2025
DOI: 10.1177/18796397251323549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, 2025. Verfasst von Rebecca Lm Fuller und 10 weiteren Autor:innen. Beteiligte Einrichtung: CHDI Management, Inc., the company that manages the scientific activities of CHDI Foundation, Inc., Princeton, NJ, USA. Hauptthemen laut MEDLINE: Huntington Disease, Patient Reported Outcome Measures, Severity of Illness Index. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CHDI Foundation.
Abstract (Originalsprache)
Background
Current functional rating scales are not sensitive to the earliest functional changes in Huntington's disease (HD).
Objective
The Functional Rating Scale 2.0 (FuRST 2.0) is a patient-reported outcome (PRO) measure designed to be sensitive to the initial functional changes in HD, specifically stage 2 and mild stage 3, as defined by the Huntington's Disease Integrated Staging System (HD-ISS).
Methods
We followed standard assessment development methodology to create a PRO. Study 1 consisted of a Delphi panel which analyzed data from focus groups comprised of people with HD and companions from 6 countries. This was followed by four rounds of cognitive interviews through which we evaluated respondents’ comprehension of the instructions, understanding of question and response options, and comfort with the material. Informal advice from a regulatory agency was garnered throughout the process.
Results
Concerns from the target population and regulators regarding instructions, questions, response options, and comfort with the material were addressed through modifications to the scale's wording and format.
Conclusions
We developed the FuRST 2.0 official working document (OWD), the penultimate version of the scale, using focus groups, a Delphi panel, iterative rounds of cognitive interviewing, and informal regulatory advice. Its psychometric properties are being evaluated in the FOCUS-HD validation studies from which the final version of the scale will be derived. The FuRST 2.0 OWD is available for use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CHDI Management, Inc., the company that manages the scientific activities of CHDI Foundation, Inc., Princeton, NJ, USA.
- Qualitative Research and Evaluation Consulting, Westborough, MA, USA.
- Department of Psychiatry, University of Iowa, Iowa City, IA, USA.
- ClinMed LLC, Monroe Township, NJ, USA.
- Rush University Medical Center, Chicago, IL, USA.
ORCID-Profile: Rebecca Lm Fuller, Pua Feigenbaum, Swati Sathe, Prachi Dalal, Cheryl J Fitzer-Attas, Cristina Sampaio, Glenn T Stebbins
Förderung
- CHDI Foundation
Zitieren
APA
Fuller, R. L., Feigenbaum, P., LaPelle, N., Sathe, S., Dalal, P., Vaidya, J. G., Sinha, N., Roché, M., Fitzer-Attas, C. J., Sampaio, C., & Stebbins, G. T. (2025). Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease. Journal of Huntington's Disease. https://doi.org/10.1177/18796397251323549
Vancouver
Fuller RL, Feigenbaum P, LaPelle N, Sathe S, Dalal P, Vaidya JG, et al. Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease. Journal of Huntington's Disease. 2025. doi:10.1177/18796397251323549
BibTeX
@article{Fuller2025,
author = {Fuller, Rebecca Lm and Feigenbaum, Pua and LaPelle, Nancy and Sathe, Swati and Dalal, Prachi and Vaidya, Jatin G and Sinha, Neha and Roché, Matthew and Fitzer-Attas, Cheryl J and Sampaio, Cristina and Stebbins, Glenn T},
title = {Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease},
journal = {Journal of Huntington's Disease},
year = {2025},
doi = {10.1177/18796397251323549}
}
EUVIMED